If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    -0.20 (-0.28%)
Bid:
71.80
Ask:
72.30
Spread: 0.50 (0.696%)
Market Cap: £684.34m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CEO succession

16 Apr 2024 07:00

RNS Number : 7054K
Dr. Martens PLC
16 April 2024
 

This announcement contains inside information.

 

16 April 2024

Dr. Martens plc

CEO succession

 

Dr. Martens plc ('the Company') announces that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board is delighted to announce that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season.

Paul Mason, Chair, said "Kenny's contribution to Dr. Martens has been immense. He has spear-headed a brand-first DTC-driven strategy, achieving significant growth, with pairs more than doubling during his tenure. With his focus on product, brand and custodianship he has instilled a strong culture through the organisation. I am grateful that he will ensure an orderly transition to Ije over the coming year, alongside our incoming CFO Giles Wilson."

Lynne Weedall, Senior Independent Director and Chair of the Nomination Committee, said "Ije is an inspirational leader and his experience in helping drive DTC-led growth at Apple will be highly relevant in the coming years. He knows the Company well, having been a Non-Executive Director for three years and we are already benefiting from his brand expertise since he joined as CBO in February. We are delighted that he will be the next CEO."

Kenny Wilson, CEO, said, "Dr. Martens is an incredible brand powered by our fantastic people. After six years in the role, I feel that the time is right to hand over this year, and I am excited that Ije will be my successor. I have enjoyed working with Ije, both as a Board member and in the executive leadership team in recent months, and I have seen his brand knowledge and passion first-hand. I look forward to working with him closely in the year ahead."

Ije Nwokorie, CBO, said, "I am thrilled that I will be the next CEO of Dr. Martens. We have a phenomenal brand, an excellent product range and a passionate culture. I am looking forward to working with Kenny through this transition year."

 

This announcement has been made in accordance with the requirements of 9.6.11 of the UK Listing Rules. The Company confirms that there is no further information required to be disclosed pursuant to paragraph 9.6.13 of the UK Listing Rules.

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465

Beth Callum, Investor Relations Manager Beth.Callum@drmartens.com +44 203 995 2644

 

Press

H/Advisors Maitland +44 207 379 5151

Katharine Spence +44 7384 535739

Gill Hammond, Director of Communications +44 7384 214248

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Company Secretary.

Notes to editors

Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAPLSFAPLEFA
Date   Source Headline
1st Jun 20227:00 amRNSFinal Results
27th Apr 20228:57 amRNSDirector Declaration
1st Apr 20223:18 pmRNSTotal Voting Rights
1st Apr 20222:01 pmRNSBlock listing Interim Review
30th Mar 20227:00 amRNSBlock Listing Application
22nd Mar 20227:43 amRNSDirector Declaration
31st Jan 20224:23 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSTrading Statement
11th Jan 20224:11 pmRNSDirector/PDMR Shareholding
10th Jan 20225:15 pmRNSHolding(s) in Company
6th Jan 20225:30 pmRNSDr Martens
6th Jan 20227:00 amRNSResult of Secondary Placing in Dr. Martens
5th Jan 20225:12 pmRNSProposed Secondary Placing in Dr. Martens plc
13th Dec 20211:33 pmRNSChange of Auditor
9th Dec 20217:00 amRNSHalf-year Report
1st Nov 202112:53 pmRNSTotal Voting Rights
30th Sep 20218:45 amRNSBlock Listing Application
15th Sep 20217:00 amRNSDirector/PDMR Shareholding
29th Jul 20211:06 pmRNSResult of AGM
29th Jul 20217:00 amRNSTrading Statement
12th Jul 202110:00 amRNSPrior year quarterly revenue figures
1st Jul 20219:00 amRNSAnnual Financial Report
25th Jun 202112:46 pmRNSHolding(s) in Company
23rd Jun 20216:19 pmRNSHolding(s) in Company
21st Jun 202110:39 amRNSDirector/PDMR Shareholding
18th Jun 20213:16 pmRNSHolding(s) in Company
17th Jun 20217:00 amRNSFinal Results
16th Jun 20215:40 pmRNSHolding(s) in Company
13th Apr 20217:00 amRNSAppointment of Joint Corporate Brokers
10th Feb 20219:00 amRNSDirector/PDMR Shareholding
9th Feb 20211:41 pmRNSHolding(s) in Company
5th Feb 202112:52 pmRNSHolding(s) in Company
5th Feb 20219:20 amRNSExercise of Over-allotment Option
4th Feb 20215:20 pmRNSHolding(s) in Company
3rd Feb 20218:00 amRNSAdmission to Trading on the London Stock Exchange
3rd Feb 20218:00 amRNSTotal Voting Rights
1st Feb 20214:53 pmRNSDirector/PDMR Shareholding
29th Jan 202111:18 amRNSStabilisation Notice
29th Jan 202110:48 amRNSApproval and Publication of Prospectus
29th Jan 20217:00 amRNSAnnouncement of Offer Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.